259 related articles for article (PubMed ID: 21355939)
1. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
[TBL] [Abstract][Full Text] [Related]
3. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
4. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
5. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
Johnson B; Richert T
J Psychoactive Drugs; 2014; 46(5):427-35. PubMed ID: 25364995
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
7. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists.
Lawrinson P; Roche A; Terao H; Le PP
Drug Alcohol Rev; 2008 Jan; 27(1):47-53. PubMed ID: 18034381
[TBL] [Abstract][Full Text] [Related]
8. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
[TBL] [Abstract][Full Text] [Related]
9. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.
Johanson CE; Arfken CL; di Menza S; Schuster CR
Drug Alcohol Depend; 2012 Jan; 120(1-3):190-5. PubMed ID: 21862241
[TBL] [Abstract][Full Text] [Related]
10. Methadone and buprenorphine prescribing patterns of Victorian general practitioners: their first 5 years after authorisation.
Longman C; Lintzeris N; Temple-Smith M; Gilchrist G
Drug Alcohol Rev; 2011 Jul; 30(4):355-9. PubMed ID: 21355929
[TBL] [Abstract][Full Text] [Related]
11. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
Johnson B; Richert T
Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
[TBL] [Abstract][Full Text] [Related]
12. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
Winstock AR; Lea T
Subst Use Misuse; 2010; 45(1-2):240-52. PubMed ID: 20025451
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
14. Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients' attitudes and norms.
Johnson B; Richert T
J Subst Abuse Treat; 2015 Jul; 54():50-5. PubMed ID: 25744650
[TBL] [Abstract][Full Text] [Related]
15. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
16. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.
Winstock AR; Lea T; Sheridan J
Addiction; 2010 Feb; 105(2):335-42. PubMed ID: 20078490
[TBL] [Abstract][Full Text] [Related]
17. What is diversion of supervised buprenorphine and how common is it?
Winstock AR; Lea T; Sheridan J
J Addict Dis; 2009 Jul; 28(3):269-78. PubMed ID: 20155596
[TBL] [Abstract][Full Text] [Related]
18. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
Winstock AR; Lea T; Ritter A
Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Winstock AR; Lea T; Sheridan J
Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
[TBL] [Abstract][Full Text] [Related]
20. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
Richert T; Johnson B
Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
